Table 2.
Late toxicity in the first cohort from patient medical records
| Toxicity | CF-PMRT n (%) N = 660 |
HF-PMRT n (%) N = 980 |
p-value |
|---|---|---|---|
| Skina | < 0.001 | ||
| N | 641 | 942 | |
| Grade 0 | 276 (43) | 482 (51) | |
| Grade 1 | 355 (55) | 427 (45) | |
| Grade 2 | 10 (2) | 23 (3) | |
| Grade 3 | 0 (0) | 10 (1) | |
| Subcutaneous tissuea | < 0.001 | ||
| N | 641 | 942 | |
| Grade 0 | 358 (56) | 622 (66) | |
| Grade 1 | 267 (42) | 225 (24) | |
| Grade 2 | 16 (2) | 95 (10) | |
| Lungb | < 0.001 | ||
| N | 641 | 955 | |
| No | 539 (84) | 473 (50) | |
| Yes | 102 (16) | 482 (50) | |
| Heartb | 0.272 | ||
| N | 641 | 942 | |
| No | 630 (98) | 932 (99) | |
| Yes | 11 (2) | 10 (1) | |
| Lymphedemab | 0.072 | ||
| N | 640 | 942 | |
| No | 618 (97) | 924 (98) | |
| Yes | 22 (3) | 18 (2) |
CF-PMRT Conventional fractionated post mastectomy radiotherapy, HF-PMRT Hypofractionated post mastectomy radiotherapy, N number
aRTOG/EORTC Late Radiation Morbidity Scoring Schema [11]
bno record of grading, information of any symptoms that related to the toxicities only